Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.

Zubin PunthakeeStephanie HallNatalia McInnesDiana SherifaliKate TsiplovaFaith R KiraboThomas P P RansomStewart B HarrisHeather A LochnanRonald J SigalMahua GhoshTamara SpaicUlagamadesan Venkatesannull null

Published in: Diabetes, obesity & metabolism (2024)

An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse within 1 year without sustained remission.

Keyphrases

type diabetes
glycemic control
disease activity
randomized controlled trial
ulcerative colitis
rheumatoid arthritis
cardiovascular disease
insulin resistance
systemic lupus erythematosus
adipose tissue
free survival
skeletal muscle